On September 3, 2023, Kirsten Gruis, M.D. resigned from her position as Chief Medical Officer of DiaMedica Therapeutics Inc. (?DiaMedica? or the ?Company?), effective as of August 31, 2023, although she agreed to stay on as an independent consultant with the Company for nine months to assist with the transition of her duties and responsibilities and to complete certain additional projects. To replace Dr. Gruis immediately on an interim basis while DiaMedica completes its search for a permanent Chief Medical Officer, DiaMedica has engaged as an independent consultant, Jordan Dubow, M.D., an experienced vascular neurologist, with extensive Chief Medical Officer experience, including overseeing stroke trials, to expedite site engagement and patient recruitment in DiaMedica?s Phase 2/3 ReMEDy2 clinical trial of DM199 in acute ischemic stroke patients.

Dr. Dubow is a stroke and movement disorders trained neurologist. He has served as a full time or consulting Chief Medical Officer for eight companies, both public and private. During his industry career, he has worked on 16 new drug applications (?NDAs?) through the Division of Neurology of the U.S. Food and Drug Administration and has worked with several stroke clinical trial programs. Dr. Dubow was previously the chief medical officer at Paragon Biosciences, Avadel Pharmaceuticals, and Marathon Pharmaceuticals.

He also served as vice president of CNS Therapeutic Strategy at Esteve Pharmaceuticals, responsible for evaluating in-licensing candidates and providing regulatory and clinical support for its development pipeline. He has held leadership positions at Cynapsus Therapeutics and started his pharmaceutical career at AbbVie as a medical director in neuroscience clinical development. He has extensive development and regulatory experience in the United States, as well as Europe, Japan, Canada, and Australia.